Shanghai Huaota Biopharmaceutical Co., Ltd.赞助的临床试验
总计1478个结果
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd完全的原发性骨髓纤维化 (PMF) | 真性红细胞增多症后骨髓纤维化(Post-PV MF) | 原发性血小板增多症后骨髓纤维化(Post-ET MF)中国
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd终止
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.尚未招聘
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd尚未招聘
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.尚未招聘
-
Staidson (Beijing) Biopharmaceuticals Co., Ltd招聘中
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd招聘中
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.招聘中
-
Jiangsu Alphamab Biopharmaceuticals Co., Ltd尚未招聘
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd尚未招聘
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.尚未招聘活动性中度至重度 Graves 眼眶病
-
Chengdu Easton Biopharmaceuticals Co,Ltd招聘中
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd终止
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd完全的
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd完全的